ABSCF Stock Chart & Stats
$1.45
$0.10(12.50%)
At close: 4:00 PM EST
$1.45
$0.10(12.50%)
Day’s Range― - ―
52-Week Range$1.12 - $1.45
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
$61.65M
Enterprise Value$55.46M
Total Cash (Recent Filing)$10.18M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Sep 25, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding69,776,230
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue47.24
Enterprise Value/Gross Profit77.03
Enterprise Value/Ebitda-45.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$1.40M
Bulls Say, Bears Say
Bulls Say
Multi-indication PipelineA single, broad-spectrum small‑molecule (masitinib) being developed across oncology and inflammatory/neurological indications creates durable program optionality. Multi-indication development diversifies clinical and commercial risk, increasing long‑term chances at revenue generation from more than one market.
Sharp Debt ReductionMaterial decline in gross debt by 2025 meaningfully lowers near‑term refinancing pressure and interest burden. This durable improvement in liabilities reduces solvency strain and extends strategic flexibility for clinical programs, assuming cash burn is managed.
Improving Revenue TrendConsistent revenue growth, including a ~14% increase in 2025, signals emerging commercial or partnership receipts and incremental market traction. If sustained, this trend supports longer‑term scaling and reduces reliance solely on financing to fund R&D and operations.
Bears Say
Persistent Deep LossesChronic operating and net losses erode financial resilience and make self‑funding of clinical development unlikely. Over time, sustained unprofitability increases reliance on external capital, heightens dilution risk, and constrains the company’s ability to invest countercyclically or scale commercial activities.
Negative Shareholder EquityPersistent negative equity reflects accumulated deficits and a fragile capital structure, limiting borrowing capacity and raising creditor and partner concerns. Structurally, this reduces financial flexibility and increases vulnerability to adverse trial or regulatory outcomes.
Resumed Cash BurnA return to substantial negative operating and free cash flow in 2025 reintroduces acute liquidity and funding risk. Over the medium term this necessitates new capital raises or partnerships, which can dilute shareholders and divert management focus from execution of clinical and commercial plans.
AB Science SA News
ABSCF FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest stock price was $1.12 and its highest was $1.45 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is $61.65M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Sep 25, 2026 which is in 80 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on May 13, 2026. The company reported -$0.081 earnings per share for the quarter, the consensus estimate of -$0.081 by $0.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA does not currently pay dividends.
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate is -0.08.
How many shares outstanding does AB Science SA have?
AB Science SA has 69,776,230 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -$0.081 in its last earnings report, expectations of -$0.081. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in ABSCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.